Related Experiment Videos
[Captopril in congestive heart failure (author's transl)]
Klinische Wochenschrift
|February 1, 1982
Summary
Captopril, an angiotensin-I converting enzyme inhibitor, effectively treats congestive heart failure by reducing cardiac preload and afterload. This oral medication improves patient outcomes with manageable side effects, necessitating regular monitoring.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Context:
- Congestive heart failure (CHF) involves angiotensin-mediated vasoconstriction and aldosterone secretion, leading to increased cardiac workload.
- Current treatments aim to mitigate these effects and improve cardiac function.
Purpose:
- To evaluate the efficacy and safety of captopril, an angiotensin-I converting enzyme inhibitor, in treating congestive heart failure.
- To assess the hemodynamic effects, dosage, and adverse reactions associated with captopril therapy.
Summary:
- Captopril inhibits angiotensin-I converting enzyme, reversing angiotensin-mediated vasoconstriction and aldosterone secretion in CHF patients.
- This action reduces cardiac preload and afterload, leading to increased cardiac output and decreased pulmonary pressures.
- Administered orally (50-150 mg daily), captopril shows maximum hemodynamic effect within 45-90 minutes, with no observed tolerance over 18 months.
Impact:
- Captopril improves the clinical status of patients with congestive heart failure.
- Reversible side effects include skin rash and taste loss; serious effects like leucopenia and renal failure necessitate regular blood and urine analysis.